Date: 14-Aug-2019

Windgap Medical partners with ALK-Abello to commercialize Epinephrine Autoinjector to treat anaphylactic shock

Windgap Medical, Inc., a privately-held pharmaceutical company, announced that it has entered into a strategic partnership with ALK-Abelló, A/S (ALK) to commercialize the companys epinephrine autoinjector (EAI) for the treatment of anaphylactic shock. Under its agreement with Windgap, ALK has exclusive, worldwide sales and distribution rights for the Windgap EAI in exchange for up-front, technical, and sales milestone payments along with tiered royalties on net sales in the USA, along with a split of net profit for products sold outside of the USA.